ES2673426T3 - Compuestos de tioacetato, composiciones y métodos de uso - Google Patents

Compuestos de tioacetato, composiciones y métodos de uso Download PDF

Info

Publication number
ES2673426T3
ES2673426T3 ES15166826.6T ES15166826T ES2673426T3 ES 2673426 T3 ES2673426 T3 ES 2673426T3 ES 15166826 T ES15166826 T ES 15166826T ES 2673426 T3 ES2673426 T3 ES 2673426T3
Authority
ES
Spain
Prior art keywords
compound
alkyl
formula
halogen
och3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15166826.6T
Other languages
English (en)
Inventor
Samedy Ouk
Esmir Gunic
Jean-Michel Vernier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Ardea Biociences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45348850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2673426(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ardea Biociences Inc filed Critical Ardea Biociences Inc
Application granted granted Critical
Publication of ES2673426T3 publication Critical patent/ES2673426T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/70—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de la Fórmula (I):**Fórmula** en donde: Ra y Rb se seleccionan de H, halógeno, C1 a C6 alquilo; o Ra y Rb, junto con el átomo de carbono al que están unidos, forman un anillo de 3-, 4-, 5- o 6-miembros, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S; M es H, C1-3 alquilo o un catión farmacéuticamente aceptable; X1 es N, CH, C(halógeno) o C(C1-C4 alquilo); X2 es N o CH; X3 es N, CH, C(halógeno) o C(C1-C4 alquilo); X4 es N o CH; en donde uno de X1, X2, X3 o X4 es N; Y1 es N o CR1; Y2 es N o CR2; R1 es H, CF3, CH3, OCH3, F o Cl; R2 es H, metilo, etilo, propilo, isopropilo, terc-butilo, ciclopropilo, ciclobutilo, CF3, OH, OCH3, etoxi, SH, SCH3, SCH2CH3, CH2OH, C(CH3)2OH, Cl, F, CN, COOH, COOR2', CONH2, CONHR2' o SO2NH2; en donde R2' es H o C1-3 alquilo; R3 es H, halógeno, -CN, C1 a C6 alquilo, C1 a C6 alcoxi; y R4 es H, halógeno, -CN, C1 a C6 alquilo, C1 a C6 alcoxi; o R3 y R4 junto con los átomos de carbono a los que están unidos forman un anillo de 5- o 6-miembros opcionalmente sustituido, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S, en donde dicho anillo de 5- o 6- miembros es un anillo saturado, uno insaturado o uno aromático; con la condición de que el compuesto de la Fórmula (I) no sea ácido 1-(3-(4-cianofenil)piridin-4- iltio)ciclopropanocarboxílico.

Description

5
10
15
20
25
30
35
40
45
50
55
60
65
DESCRIPCIÓN
Compuestos de tioacetato, composiciones y métodos de uso Antecedentes de la invención
El ácido úrico es el resultado de la oxidación de la xantina. Los trastornos del metabolismo del ácido úrico incluyen, entre otros, policitemia, metaplasia mieloide, gota, ataque recurrente de gota, artritis gotosa, hiperuricemia, hipertensión, enfermedad cardiovascular, enfermedad coronaria, síndrome de Lesch-Nyhan, síndrome de Kelley-Seegmiller, enfermedad renal, cálculos renales, insuficiencia renal, inflamación de las articulaciones, artritis, urolitiasis, plumbismo, hiperparatiroidismo, psoriasis o sarcoidosis. Se puede hacer referencia al documento US2010/056464 y al documento WO2011/159840.
Resumen de la invención
En ciertas modalidades, se proporcionan aquí compuestos, métodos y composiciones, por ejemplo, para la modulación de niveles de ácido úrico en suero (AUs) o el tratamiento de la gota o hiperuricemia en individuos que lo necesitan. En algunas modalidades, tales composiciones comprenden y tales métodos comprenden la administración a un individuo que lo necesita de una cantidad eficaz de un compuesto de la Fórmula I:
imagen1
en donde:
Ra y Rb se seleccionan de H, halógeno, C1 a Ce alquilo; o Ra y Rb, junto con el átomo de carbono al que están unidos, forman un anillo de 3-, 4-, 5- o 6-miembros, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N yS;
M es H, C1-3 alquilo o un catión farmacéuticamente aceptable;
X1 es N, CH, C(halógeno) o C(C1-C4 alquilo);
X2 es N o CH;
X3 es N, CH, C(halógeno) o C(C1-C4 alquilo);
X4 es N o CH; en donde uno de X1, X2, X3 o X4 es N;
Y1 es N oCR1;
Y2 es N o CR2;
R1 es H, CF3, CH3, OCH3, F o Cl;
R2 es H, metilo, etilo, propilo, isopropilo, tere-butilo, ciclopropilo, ciclobutilo, CF3, OH, OCH3, etoxi, SH, SCH3, SCH2CH3, CH2OH, C(CH3)2OH, Cl, F, CN, COOH, COOR2', CONH2, CONHR2' o SO2NH2; en donde R2' es H o C1-3 alquilo;
R3 es H, halógeno, -CN, C1 a Ce alquilo, C1 a Ce alcoxi; y R4 es H, halógeno, -CN, C1 a Ce alquilo, C1 a Ce alcoxi; o
R3 y R4 junto con los átomos de carbono a los que están unidos forman un anillo de 5- o e-miembros opcionalmente sustituido, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S, en donde dicho anillo de 5- o e- miembros puede ser un anillo saturado, insaturado o aromático;
(i) el compuesto de la Fórmula (I) no es ácido 1-(3-(4-cianofenil)piridin-4-iltio)ciclopropanocarboxílico.
En ciertas modalidades, se proporciona un compuesto de la Fórmula (I), en donde uno de X1, X2, X3 o X4 es N. Ciertas modalidades específicas proporcionadas en la presente descripción describen un compuesto de la Fórmula (I-A), (I-B), (I-C)o(I-D):
imagen2
5
10
15
20
25
30
35
40
45
50
55
60
65
En algunas modalidades de la presente descripción se proporciona un compuesto de la Fórmula (I), en donde R3 es H, CH3, OCH3, CF3, F o Cl; y R4 es H, CH3, OCH3, CF3, F o Cl. En ciertas modalidades específicas, R3 y R4 son ambas H.
Algunas modalidades proporcionadas en la presente descripción describen un compuesto de la Fórmula (I), en donde R3 y R4 junto con los átomos de carbono a los que están unidos forman un anillo de 5- o 6-miembros opcionalmente sustituido, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S, en donde dicho anillo de 5- o 6- miembros puede ser un anillo saturado, insaturado o aromático.
Ciertas modalidades proporcionadas en la presente descripción describen un compuesto de la Fórmula (I), en donde R3 y R4 junto con los átomos de carbono a los que están unidos forman un anillo aromático de 6-miembros opcionalmente sustituido. Ciertas modalidades específicas proporcionadas en la presente descripción describen un compuesto de la Fórmula (I-K):
imagen3
en donde n es 1, 2, 3 o 4; y
cada R5 se selecciona independientemente de H, metilo, etilo, propilo, isopropilo, tere-butilo, ciclopropilo, ciclobutilo, CF3, OH, OCH3, etoxi, SH, SCH3, SCH2CH3, CH2OH, C(CH3)2OH, Cl, F, CN, COOH, COOR5', CONCH2, CONHR5' o SO2NH2; en donde R5' es H o C1-3 alquilo.
En ciertas modalidades de la presente descripción se proporciona un compuesto de la Fórmula (I), en donde Ra es H o CH3; y Rb es H o CH3. En modalidades específicas, Ra y Rb son ambos CH3. Ciertas modalidades específicas proporcionadas en la presente descripción describen un compuesto de la Fórmula (I-L):
imagen4
En otras modalidades o modalidades adicionales, X1 es CH; X2 es N; X3 es CH; y X4es CH. En otras modalidades o modalidades adicionales, Y1 es CR1; y Y2 es CR2.
Ciertas modalidades específicas proporcionadas en la presente descripción describen un compuesto de la Fórmula (IB), seleccionado del grupo que consiste en:

Claims (12)

  1. 5
    10
    15
    20
    25
    30
    35
    40
    45
    50
    55
    60
    65
    Reivindicaciones
    1. Un compuesto de la Fórmula (I):
    imagen1
    en donde:
    Ra y Rb se seleccionan de H, halógeno, Ci a C6 alquilo; o Ra y Rb, junto con el átomo de carbono al que están unidos, forman un anillo de 3-, 4-, 5- o 6-miembros, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S;
    M es H, C1-3 alquilo o un catión farmacéuticamente aceptable;
    X1 es N, CH, C(halógeno) o C(C1-C4 alquilo);
    X2 es N o CH;
    X3 es N, CH, C(halógeno) o C(Ci-C4 alquilo);
    X4 es N o cH; en donde uno de X1, X2, X3 o X4 es N;
    Y1 es NoCR1;
    Y2 es N o CR2;
    R1 es H, CF3, CH3, OCH3, F o Cl;
    R2 es H, metilo, etilo, propilo, isopropilo, tere-butilo, ciclopropilo, ciclobutilo, CF3, OH, OCH3, etoxi, SH, SCH3, SCH2CH3, CH2OH, C(CH3)2OH, Cl, F, CN, COOH, COOR2', CONH2, CONHR2' o SO2NH2; en donde R2' es H o C1-3 alquilo;
    R3 es H, halógeno, -CN, C1 a C6 alquilo, C1 a C6 alcoxi; y
    R4 es H, halógeno, -CN, C1 a C6 alquilo, C1 a C6 alcoxi; o
    R3 y R4 junto con los átomos de carbono a los que están unidos forman un anillo de 5- o 6-miembros
    opcionalmente sustituido, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S, en
    donde dicho anillo de 5- o 6- miembros es un anillo saturado, uno insaturado o uno aromático;
    con la condición de que el compuesto de la Fórmula (I) no sea ácido 1-(3-(4-cianofenil)piridin-4-
    iltio)ciclopropanocarboxílico.
  2. 2. Un compuesto de la reivindicación 1, en donde:
    R3 es H, CH3, OCH3, CF3, F o Cl; and
    R4 es H, CH3, OCH3, CF3, F o Cl.
  3. 3. Un compuesto de la reivindicación 1, en donde R3 y R4 junto con los átomos de carbono a los que están unidos forman un anillo de 5- o 6-miembros opcionalmente sustituido, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S, en donde dicho anillo de 5- o 6- miembros puede ser un anillo saturado, insaturado o aromático.
  4. 4. Un compuesto de la reivindicación 3, de la Fórmula (I-K):
    imagen2
    en donde n es 1, 2, 3 o 4; y
    cada R5 se selecciona independientemente de H, metilo, etilo, propilo, isopropilo, tere-butilo, ciclopropilo, ciclobutilo, CF3, OH, OCH3, etoxi, SH, SCH3, SCH2CH3, CH2OH, C(CH3)2OH, Cl, F, CN, COOH, COOR5', CONCH2, CONHR5' o SO2NH2; en donde R5' es H o C1-3 alquilo.
  5. 5. Un compuesto de la reivindicación 1, en donde:
    Ra es H o CH3; y
    RbesHo CH3.
    5
  6. 6. Un compuesto de la reivindicación 5, de la Fórmula (I-L):
    imagen3
    20
    25
  7. 7.
    30
    35
    en donde X1 es CH;
    X2 es N;
    X3 es CH; y
    X4 es CH; y opcionalmente en donde Y1 es CR1 y Y2 es CR2.
    Un compuesto de la reivindicación 6, de la Fórmula (I-M):
    imagen4
    40 y opcionalmente en donde R1, R3 y R4 son todos H.
  8. 8. Un compuesto de la reivindicación 1, en donde Ra y Rb juntos con el átomo de carbono al que están unidos forman un anillo de 3-, 4-, 5- o 6-miembros, que contiene opcionalmente uno o dos heteroátomos seleccionados de O, N y S.
    45
  9. 9. Un compuesto de la reivindicación 1, en donde M es H.
  10. 10. Un compuesto de la Fórmula (I) de acuerdo con una cualquiera de las reivindicaciones 1 a 9 para usar en la reducción de los niveles séricos de ácido úrico en un ser humano, tratar la hiperuricemia en un humano con
    50 gota, tratar la hiperuricemia en un ser humano, tratar la gota en un ser humano, tratar o prevenir una afección
    caracterizada por niveles anormales de ácido úrico en tejidos u órganos en un individuo, y opcionalmente, en donde el compuesto se usa en combinación con un segundo agente eficaz para el tratamiento de la gota.
  11. 11. El compuesto de la Fórmula (I) como se define en las reivindicaciones 1-9 para usar de acuerdo con la
    55 reivindicación 10, en donde la afección es gota, un ataque recurrente de gota, artritis gotosa, hiperuricemia,
    hipertensión, una enfermedad cardiovascular, enfermedad coronaria, síndrome de Lesch-Nyhan, síndrome de Kelley-Seegmiller, enfermedad renal, cálculos renales, insuficiencia renal, inflamación de las articulaciones, artritis, urolitiasis, plumbismo, hiperparatiroidismo, soriasis, sarcoidosis, hipoxantina-guanina fosforribosiltransferasa (HPRT) deficiencia o una combinación de los mismos.
    60
  12. 12. El compuesto de la Fórmula (I) como se define en las reivindicaciones 1-9 para usar de acuerdo con la reivindicación 10, en donde el segundo agente es un inhibidor URAT 1, un inhibidor de xantina oxidasa, una xantina deshidrogenasa, un inhibidor de xantina oxidorreductasa, o combinaciones de estos; o, en donde el segundo agente es allopurinol, febuxostat, FYX-051, o combinaciones de los mismos.
ES15166826.6T 2010-06-16 2011-06-15 Compuestos de tioacetato, composiciones y métodos de uso Active ES2673426T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35549110P 2010-06-16 2010-06-16
US355491P 2010-06-16

Publications (1)

Publication Number Publication Date
ES2673426T3 true ES2673426T3 (es) 2018-06-21

Family

ID=45348850

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11796396.7T Active ES2459146T3 (es) 2010-06-16 2011-06-15 Compuestos de tioacetato, composiciones y métodos de uso
ES13198843.8T Active ES2551114T3 (es) 2010-06-16 2011-06-15 Compuestos de tioacetato, composiciones y métodos de uso
ES15166826.6T Active ES2673426T3 (es) 2010-06-16 2011-06-15 Compuestos de tioacetato, composiciones y métodos de uso

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES11796396.7T Active ES2459146T3 (es) 2010-06-16 2011-06-15 Compuestos de tioacetato, composiciones y métodos de uso
ES13198843.8T Active ES2551114T3 (es) 2010-06-16 2011-06-15 Compuestos de tioacetato, composiciones y métodos de uso

Country Status (41)

Country Link
US (5) US10266493B2 (es)
EP (5) EP3611167A1 (es)
JP (5) JP5551310B2 (es)
KR (2) KR101432950B1 (es)
CN (2) CN103864677B (es)
AR (1) AR081930A1 (es)
AU (1) AU2011268360B2 (es)
BR (1) BR112012032028B1 (es)
CA (1) CA2802535C (es)
CL (1) CL2012003546A1 (es)
CO (1) CO6640311A2 (es)
CR (1) CR20120649A (es)
CU (1) CU24126B1 (es)
CY (1) CY1120337T1 (es)
DK (3) DK2712861T3 (es)
DO (1) DOP2012000314A (es)
EA (1) EA022933B1 (es)
EC (1) ECSP12012353A (es)
ES (3) ES2459146T3 (es)
GT (1) GT201200339A (es)
HN (1) HN2012002664A (es)
HR (3) HRP20140391T1 (es)
HU (2) HUE025962T2 (es)
IL (2) IL223435A (es)
LT (1) LT2975025T (es)
ME (2) ME01830B (es)
MX (2) MX2012014863A (es)
MY (1) MY153039A (es)
PE (1) PE20131047A1 (es)
PH (1) PH12012502460A1 (es)
PL (3) PL2975025T3 (es)
PT (3) PT2975025T (es)
RS (3) RS54375B1 (es)
SG (2) SG186298A1 (es)
SI (3) SI2975025T1 (es)
SM (3) SMT201800304T1 (es)
TR (1) TR201808344T4 (es)
TW (2) TWI460173B (es)
UA (1) UA107115C2 (es)
WO (1) WO2011159839A2 (es)
ZA (1) ZA201209574B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels
PE20150974A1 (es) 2012-11-14 2015-07-04 Teijin Pharma Ltd Derivados de piridina
HUE037512T2 (hu) 2013-05-13 2018-08-28 Shanghai hengrui pharmaceutical co ltd Cikloalkilsav-származék, eljárás elõállítására, és felhasználása gyógyszerként
JP6322704B2 (ja) * 2013-06-27 2018-05-09 エルジー・ケム・リミテッド Ｇｐｒ１２０アゴニストとしてのビアリール誘導体
AU2015260300A1 (en) 2014-05-13 2016-12-22 Teijin Pharma Limited Pyrazine derivative
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN115925679A (zh) * 2014-12-24 2023-04-07 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
RU2721844C2 (ru) * 2014-12-29 2020-05-25 Ниппон Кемифар Ко., Лтд. Ингибиторы urat1
WO2017028762A1 (zh) * 2015-08-14 2017-02-23 广东东阳光药业有限公司 一种萘环化合物的晶型
CN105418495B (zh) * 2015-11-25 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 一种硫醚的制备方法
WO2017097182A1 (zh) * 2015-12-07 2017-06-15 成都海创药业有限公司 喹啉类化合物及其制备方法和作为尿酸盐转运体抑制剂类药物的用途
SG11201804100UA (en) * 2015-12-08 2018-06-28 Ardea Biosciences Inc Pharmaceutical composition comprising a potent inhibitor of urat1
JP6898330B2 (ja) * 2015-12-28 2021-07-07 シャンハイ フォチョン ファーマシューティカル カンパニー リミテッド インドリジン誘導体、組成物、及び使用方法
WO2017121308A1 (en) * 2016-01-11 2017-07-20 Chongqing Fochon Pharmaceutical Co., Ltd. Fused pyridine compounds, compositions and methods of use
JP6971997B2 (ja) * 2016-02-15 2021-11-24 アンスティトゥート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシャルシュ・メディカル・（インセルム） 個体における尿中シュウ酸塩濃度を低下させるための、スチリペントール及びその誘導体の使用
CN105884807A (zh) * 2016-04-26 2016-08-24 昆药集团股份有限公司 硼酸频那醇酯衍生物的制备方法、硫代乙酸盐化合物的制备方法
CN106117130A (zh) * 2016-06-28 2016-11-16 昆药集团股份有限公司 一种2‑((3‑(4‑氰基萘‑1‑基)吡啶‑4‑基)硫基)‑2‑甲基丙酸的晶型及其制备方法和药物组合物
CN106083847B (zh) * 2016-08-03 2018-10-30 山东大学 一种咪唑并吡啶巯乙酸类衍生物及其制备方法与应用
CN110121359A (zh) 2016-11-11 2019-08-13 怀特黑德生物制剂研究所 人血浆培养基
CN106748987B (zh) * 2016-11-18 2019-05-31 昆药集团股份有限公司 2-((3-(4-氰基萘-1-基)吡啶-4-基)硫基)-2-甲基丙酸钠盐的晶型
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
CN106883169A (zh) * 2017-04-01 2017-06-23 浙江永宁药业股份有限公司 一种3‑(4‑氰基‑1‑萘基)‑4‑卤代吡啶的制备方法及其应用
CN108659000B (zh) * 2017-05-03 2020-03-31 成都海创药业有限公司 杂环化合物及其制备方法
WO2019069973A1 (ja) * 2017-10-04 2019-04-11 日本たばこ産業株式会社 含窒素ヘテロアリール化合物およびその医薬用途
CN107955029B (zh) * 2017-12-07 2020-08-11 成都美域高制药有限公司 一种雷西纳德的制备方法
CN108069940B (zh) * 2017-12-20 2021-04-30 广东赛烽医药科技有限公司 硫代乙酸化合物、组合物及其应用
CN108084153A (zh) * 2017-12-20 2018-05-29 广东赛烽医药科技有限公司 吡啶基硫代乙酸化合物、组合物及其应用
CN108440397B (zh) * 2018-03-06 2020-06-05 南方医科大学 3-(萘-1-甲基取代)吡啶衍生物及其合成方法和应用
WO2019183835A1 (en) * 2018-03-28 2019-10-03 Inventisbio Shanghai Ltd. Novel salt forms of urat-1 inhibitors
CN109608432B (zh) * 2018-12-17 2022-10-11 江苏艾立康医药科技有限公司 作为urat1抑制剂的噻吩类衍生物
JP2022541482A (ja) 2019-07-16 2022-09-26 アストラゼネカ・アクチエボラーグ ベリヌラドを含む用量ダンピング耐性医薬組成物
CN114315705B (zh) * 2020-09-29 2024-02-20 杭州中美华东制药有限公司 一类urat1抑制剂及其制备方法与用途
CN114621136B (zh) * 2020-12-09 2023-11-07 江苏正大清江制药有限公司 吡啶巯乙酸类化合物及其制备方法、药学衍生物或配剂以及应用
AR124985A1 (es) * 2021-03-01 2023-05-24 Orion Corp Nuevas formas de sal de un inhibidor de cyp11a1 estructurado en 4h-piran-4-ona
EP4301749A1 (en) * 2021-03-01 2024-01-10 Orion Corporation Solid forms of a 4h-pyran-4-one structured cyp11a1 inhibitor
CN115385854B (zh) * 2021-05-19 2024-04-09 江苏正大清江制药有限公司 一种喹啉巯乙酸磺酰胺类衍生物的制备及其应用
CN113979931B (zh) * 2021-10-08 2023-06-13 南方医科大学 一种吡啶3-胺衍生物及其制备方法和应用
CN114214361A (zh) * 2022-01-07 2022-03-22 中国农业科学院兰州兽医研究所 一种urat1人源化小鼠模型的构建方法及其应用
CN117362223A (zh) * 2023-09-14 2024-01-09 河北远征药业有限公司 一种4-巯基吡啶的制备方法
WO2025060752A1 (zh) * 2023-09-19 2025-03-27 湘北威尔曼制药股份有限公司 一种硫醚衍生物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE642046A (es) * 1963-01-03
ES475100A1 (es) * 1977-11-21 1979-12-01 Hoechst Ag Un metodo para preparar acidos 1,2-benzisoxazoloxiaceticos
JPS6054310B2 (ja) 1979-02-21 1985-11-29 三井東圧化学株式会社 ピリダジン誘導体と農園芸用殺菌剤
US4889868A (en) 1984-12-20 1989-12-26 Rorer Pharmaceutical Corporation Bis-imidazolinoamino derivatives as antiallergy compounds
US5051442A (en) 1990-04-25 1991-09-24 Merrell Dow Pharmaceuticals Inc. 3-indolyl thioacetate derivatives and NMDA receptor antagonistic use thereof
DE122008000051I1 (de) 1990-11-30 2009-02-05 Teijin Ltd 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel
JPH06234732A (ja) * 1992-09-10 1994-08-23 Banyu Pharmaceut Co Ltd 置換アセトアミド誘導体
CA2105617A1 (en) * 1992-09-10 1994-03-11 Yoshikazu Iwasawa Substituted acetamide derivatives
US5344651A (en) 1993-07-23 1994-09-06 The Procter & Gamble Company Cyproterone acetate thioacetate
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5945425A (en) 1994-04-29 1999-08-31 G.D. Searle & Co. Method of using (H+ /K+)ATPase inhibitors as antiviral agents
US6017925A (en) 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
US6492372B1 (en) * 1999-01-22 2002-12-10 Elan Pharmaceuticals, Inc. Heteroaryl, heterocyclic and aryl compounds which inhibit leukocyte adhesion mediated by VLA-4
GB0108339D0 (en) 2001-04-03 2001-05-23 Syngenta Participations Ag Organics compounds
WO2006026356A2 (en) 2004-08-25 2006-03-09 Ardea Biosciences, Inc. S-TRIAZOLYL α-MERCAPTOACETANILDES AS INHIBITORS OF HIV REVERSE TRANSCRIPTASE
WO2007050087A1 (en) 2004-08-25 2007-05-03 Ardea Biosciences, Inc. N[S(4-aryl-triazol-3-yl)α -mercaptoacetyl]-p-amino benozoic acids AS HIV REVERSE TRANSCRIPTASE INHIBITORS
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
US20070135437A1 (en) * 2005-03-04 2007-06-14 Alsgen, Inc. Modulation of neurodegenerative diseases
CA2608821A1 (en) 2005-06-15 2006-12-28 Shibo Jiang Anti-viral compositions comprising heterocyclic substituted phenyl furans and related compounds
US20070099970A1 (en) * 2005-08-19 2007-05-03 Mackerell Alexander Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain
US20090131384A1 (en) 2006-03-22 2009-05-21 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with er stress
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP1939181A1 (en) 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituted carboxamides and use thereof for the stimulation of the expression of NO synthase
HRP20130900T1 (hr) * 2007-04-11 2013-11-08 Kissei Pharmaceutical Co., Ltd. Derivat (aza)indola i njegova uporaba u medicinske svrhe
BRPI0819847B1 (pt) * 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
US8173690B2 (en) 2008-09-04 2012-05-08 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
CN102186832B (zh) 2008-09-04 2014-04-02 亚德生化公司 调节尿酸含量的化合物、组合物及其使用方法
WO2010048592A1 (en) 2008-10-24 2010-04-29 Ardea Biosciences, Inc. Compositions comprising 4- (2- ( 5-br0m0-4- ( 1-cyclopropylnaphthalen-4-yl) -4h-1, 2, 4-triaz0l-3-ylthi0) acetamido -3-chlorobenzoic acid and pharmaceutically acceptable salts thereof
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
JP2012527475A (ja) * 2009-05-20 2012-11-08 アルディア バイオサイエンス，インク． 尿酸値を調節するための化合物、組成物及び方法
US20110082120A1 (en) 2009-10-05 2011-04-07 Milne Jill C Substituted thioacetic acid salicylate derivatives and their uses
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
BR112012032193A2 (pt) 2010-06-16 2019-09-24 Ardea Biosciences Inc composto, composiçoes e métodos de uso de feniltioacetato
CA2852490A1 (en) * 2011-11-03 2013-05-10 Ardea Biosciences, Inc. 3,4-di-substituted pyridine compound to reduce serum uric acid levels

Also Published As

Publication number Publication date
SMT201800304T1 (it) 2018-07-17
US8629278B2 (en) 2014-01-14
CN103864677A (zh) 2014-06-18
CL2012003546A1 (es) 2013-04-12
EP2585437A2 (en) 2013-05-01
DK2975025T3 (en) 2018-06-25
AR081930A1 (es) 2012-10-31
ES2459146T3 (es) 2014-05-08
WO2011159839A3 (en) 2012-04-19
EP3611167A1 (en) 2020-02-19
JP2014237639A (ja) 2014-12-18
JP5768166B2 (ja) 2015-08-26
WO2011159839A2 (en) 2011-12-22
TR201808344T4 (tr) 2018-07-23
JP6364515B2 (ja) 2018-07-25
ME02302B (me) 2016-06-20
SI2975025T1 (en) 2018-08-31
AU2011268360A1 (en) 2013-01-10
LT2975025T (lt) 2018-06-25
PT2975025T (pt) 2018-06-18
MY153039A (en) 2014-12-31
EP2585437B1 (en) 2014-02-12
TWI501949B (zh) 2015-10-01
IL236039A0 (en) 2015-05-31
JP5551310B2 (ja) 2014-07-16
KR101432950B1 (ko) 2014-08-21
CU24126B1 (es) 2015-08-27
CO6640311A2 (es) 2013-03-22
CY1120337T1 (el) 2019-07-10
HN2012002664A (es) 2015-06-29
AU2011268360B2 (en) 2013-10-10
EP2975025B1 (en) 2018-04-04
US20190185431A1 (en) 2019-06-20
ES2551114T3 (es) 2015-11-16
PL2712861T3 (pl) 2016-02-29
ECSP12012353A (es) 2013-01-31
SMT201400055B (it) 2014-07-07
HRP20151105T1 (hr) 2016-01-01
US10266493B2 (en) 2019-04-23
DK2712861T3 (en) 2015-10-26
CA2802535C (en) 2014-08-12
DOP2012000314A (es) 2013-06-30
EA201270803A1 (ru) 2013-05-30
SI2585437T1 (sl) 2014-07-31
KR101608604B1 (ko) 2016-04-01
DK2585437T3 (da) 2014-05-05
SG10201702527TA (en) 2017-04-27
PT2585437E (pt) 2014-04-29
CN103068801B (zh) 2014-05-14
RS53301B (sr) 2014-08-29
ME01830B (me) 2014-12-20
SG186298A1 (en) 2013-01-30
US10919858B2 (en) 2021-02-16
EA022933B1 (ru) 2016-03-31
TW201504214A (zh) 2015-02-01
MX2012014863A (es) 2013-02-15
EP3409661A1 (en) 2018-12-05
HRP20140391T1 (hr) 2014-06-06
BR112012032028B1 (pt) 2021-05-04
EP2712861B1 (en) 2015-07-29
CA2802535A1 (en) 2011-12-22
BR112012032028A2 (pt) 2016-11-08
MX343583B (es) 2016-11-10
HK1180327A1 (en) 2013-10-18
JP6112318B2 (ja) 2017-04-12
HK1219102A1 (en) 2017-03-24
KR20140037292A (ko) 2014-03-26
RS57363B1 (sr) 2018-08-31
EP2585437A4 (en) 2013-07-03
HRP20180829T1 (hr) 2018-07-27
PE20131047A1 (es) 2013-10-04
SMT201500260B (it) 2016-01-08
KR20130051469A (ko) 2013-05-20
US20130202573A1 (en) 2013-08-08
TW201211018A (en) 2012-03-16
CU20120170A7 (es) 2013-05-31
EP2975025A1 (en) 2016-01-20
PL2585437T3 (pl) 2014-07-31
PH12012502460A1 (en) 2014-11-12
EP2712861A1 (en) 2014-04-02
GT201200339A (es) 2015-02-11
HUE040209T2 (hu) 2019-02-28
JP2013528655A (ja) 2013-07-11
HUE025962T2 (en) 2016-05-30
CN103068801A (zh) 2013-04-24
JP2015199760A (ja) 2015-11-12
IL223435A (en) 2015-01-29
US20130203779A1 (en) 2013-08-08
CR20120649A (es) 2013-04-17
RS54375B1 (sr) 2016-04-28
PT2712861E (pt) 2015-11-20
US20210171466A1 (en) 2021-06-10
UA107115C2 (uk) 2014-11-25
SI2712861T1 (sl) 2016-03-31
US8541589B2 (en) 2013-09-24
PL2975025T3 (pl) 2018-09-28
CN103864677B (zh) 2016-05-18
JP2018168174A (ja) 2018-11-01
US20130281469A1 (en) 2013-10-24
TWI460173B (zh) 2014-11-11
ZA201209574B (en) 2014-05-28
JP2017122108A (ja) 2017-07-13

Similar Documents

Publication Publication Date Title
SI2975025T1 (en) Tioacetate compounds, compositions and procedures of use
CL2011001060A1 (es) Compuestos derivados de 4-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil]-piridina, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo, 3-[3-{3-(1,2,4-oxadiazol-5-il)-1h-pirazol-1-il}-metil)-fenilo; procedimiento de preparacion; composicion farmaceutica; utiles para tratar enfermedades cancerosas o tumorales.
GEP20156250B (en) 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
MY187988A (en) Composition for treating hyperlipidemia comprising oxyntomodulin derivative
RU2016137181A (ru) Противофиброзные пиридиноны
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
WO2007101864A3 (en) Compounds that modulate ppar activity, their preparation and use
EA201590748A1 (ru) Противовирусные соединения против rsv
AR124688A2 (es) Una pirimidina sulfonamida o un tautómero del mismo, o una sal farmacéuticamente aceptable del mismo
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
JP2011037901A5 (es)
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
EA201000550A1 (ru) Производные тиазола
JP2017528475A5 (es)
BRPI0811745A2 (pt) Uso de compostos de 4-(pirrolidin-1-il)quinolina para matar micro-organismos clinicamente latentes
BRPI0815048B8 (pt) derivados de fenóxi-pirrolidinas, seus usos e composições farmacêuticas
RU2017110211A (ru) ИНГИБИТОРЫ α-АМИНО-β-КАРБОКСИМУКОНАТ-ε-СЕМИАЛЬДЕГИД-ДЕКАРБОКСИЛАЗЫ
EA200802407A1 (ru) Замещенные аминопиразолопиридины и их соли, их получения и фармацевтические композиции, которые их содержат
EA200602273A1 (ru) Замещённые гетероарильные и фенилсульфамоильные соединения
PH12014500997A1 (en) 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
FR2968950B1 (fr) Composition cosmetique comprenant un compose d'acide cucurbique
AR082787A1 (es) Lactonas macrociclicas y su uso y sus combinaciones con otras sustancias activas
NO20091182L (no) 2-fenoksypyrimidinonanaloger
NO20064615L (no) Substituerte heteroaryl- og fenylsulfamoylforbindelser